New EACS 2025 data show once-weekly islatravir and lenacapavir maintain HIV viral suppression for 96 weeks with no resistance ...

The biopharma will aim to bolster its pipeline, with plans to present updated results for novel long-acting combination ...

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...

South Africa's health minister has called lenacapavir, the first twice-yearly HIV prevention jab, a "groundbreaking" tool ...

ViiV Healthcare, a healthcare company founded by Pfizer (NYSE:PFE) and GSK (NYSE:GSK), announced on Wednesday that its ...

The US Department of State has announced a life-saving development to bring US-based Gilead Sciences’ breakthrough drug ...

The HIV-prevention pill PrEP will now be covered under most insurance plans. Its name is short for pre-exposure prophylaxis. Supporters of the move to make it free to those who are insured call it a ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...

The "miracle tool" HIV medicine lenacapavir will be sold in South Africa from as early as March or April 2026 according to ...

KZN to receive Lenacapavir,new long-acting HIV prevention injection. Minister Motsoaledi confirms rollout to 360 clinics, for ...

A growing trend of injecting the blood of other drug users to get a quick high, a practice called “bluetoothing”, has been ...

Recent trends indicate a disturbing comeback of HIV/AIDS in parts of the Pacific, as the World Health Organisation prepares ...